Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era-Reference-Cited by-同舟云学术

Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era

Published:2011-12-27 Issue:17 Volume:118 Page:4166-4172
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Takahashi Hiroyuki,Tomita Naoto,Yokoyama Masahiro,Tsunoda Saburo,Yano Takahiro,Murayama Kayoko,Hashimoto Chizuko,Tamura Kazuo,Sato Kazuya,Ishigatsubo Yoshiaki

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27381/fullpdf

Reference14 articles.

1. A predictive model for aggressive non-Hodgkin's lymphoma;Shipp;N Engl J Med,1993

2. State-of-the-art therapeutics: diffuse large B-cell lymphoma;Coiffier;J Clin Oncol,2005

3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP;Sehn;Blood,2007

4. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era;Tomita;Cancer Sci

5. Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy;Vega;Arch Pathol Lab Med,2006

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma with extranodal involvement;Clinical and Translational Oncology;2024-07-31

2. Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma;Cytometry Part B: Clinical Cytometry;2024-06-21

3. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors;International Forum of Allergy & Rhinology;2024-01-02

4. The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma;Genes & Diseases;2024-01

5. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement;Frontiers in Immunology;2023-08-21